Literature DB >> 34326050

Development of National Cancer Database for Cost and Quality of Life (CaDCQoL) in India: a protocol.

Shankar Prinja1, Jyoti Dixit2, Nidhi Gupta3, Nikita Mehra4, Ashish Singh5, Manjunath Nookala Krishnamurthy6, Dharna Gupta2, Kavitha Rajsekar7, Jayachandran Perumal Kalaiyarasi4, Partha Sarathi Roy8, Prabhat Singh Malik9, Anisha Mathew9, Awadhesh Pandey10, Pankaj Malhotra11, Sudeep Gupta12, Lalit Kumar9, Amal Kataki13, Gurpreet Singh14.   

Abstract

INTRODUCTION: The rising economic burden of cancer on healthcare system and patients in India has led to the increased demand for evidence in order to inform policy decisions such as drug price regulation, setting reimbursement package rates under publicly financed health insurance schemes and prioritising available resources to maximise value of investments in health. Economic evaluations are an integral component of this important evidence. Lack of existing evidence on healthcare costs and health-related quality of life (HRQOL) makes conducting economic evaluations a very challenging task. Therefore, it is imperative to develop a national database for health expenditure and HRQOL for cancer. METHODS AND ANALYSIS: The present study proposes to develop a National Cancer Database for Cost and Quality of Life (CaDCQoL) in India. The healthcare costs will be estimated using a patient perspective. A cross-sectional study will be conducted to assess the direct out-of-pocket expenditure (OOPE), indirect cost and HRQOL among cancer patients who will be recruited at seven leading cancer centres from six states in India. Mean OOPE and HRQOL scores will be estimated by cancer site, stage of disease and type of treatment. Economic impact of cancer care on household financial risk protection will be assessed by estimating prevalence of catastrophic health expenditures and impoverishment. The national database would serve as a unique open access data repository to derive estimates of cancer-related OOPE and HRQOL. These estimates would be useful in conducting future cost-effectiveness analyses of management strategies for value-based cancer care. ETHICS AND DISSEMINATION: Approval was granted by Institutional Ethics Committee vide letter no. PGI/IEC-03/2020-1565 of Post Graduate Institute of Medical Education and Research, Chandigarh, India. The study results will be published in peer-reviewed journals and presented to the policymakers at national level. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  health economics; health policy; protocols & guidelines; public health; radiation oncology

Year:  2021        PMID: 34326050     DOI: 10.1136/bmjopen-2020-048513

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  3 in total

1.  Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.

Authors:  Nidhi Gupta; Dharna Gupta; Jyoti Dixit; Nikita Mehra; Ashish Singh; Manjunath Nookala Krishnamurthy; Gaurav Jyani; Kavitha Rajsekhar; Jayachandran Perumal Kalaiyarasi; Partha Sarathi Roy; Prabhat Singh Malik; Anisha Mathew; Pankaj Malhotra; Sudeep Gupta; Lalit Kumar; Amal Kataki; Shankar Prinja
Journal:  Appl Health Econ Health Policy       Date:  2022-05-10       Impact factor: 3.686

2.  Cost Effectiveness of Bevacizumab Plus Chemotherapy for the Treatment of Advanced and Metastatic Cervical Cancer in India-A Model-Based Economic Analysis.

Authors:  Nidhi Gupta; Prerika Nehra; Akashdeep Singh Chauhan; Nikita Mehra; Ashish Singh; Manjunath Nookala Krishnamurthy; Kavitha Rajsekhar; Jayachandran Perumal Kalaiyarasi; Partha Sarathi Roy; Prabhat Singh Malik; Anisha Mathew; Pankaj Malhotra; Amal Chandra Kataki; Jyoti Dixit; Sudeep Gupta; Lalit Kumar; Shankar Prinja
Journal:  JCO Glob Oncol       Date:  2022-03

Review 3.  Comprehensive value-based cancer care in India: Opportunities for systems strengthening.

Authors:  Afsan Bhadelia
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.